HC Wainwright Reaffirms Buy Rating for Verona Pharma (NASDAQ:VRNA)

HC Wainwright reiterated their buy rating on shares of Verona Pharma (NASDAQ:VRNA) in a research report report published on Tuesday, Benzinga reports. HC Wainwright currently has a $36.00 price objective on the stock. HC Wainwright also issued estimates for Verona Pharma’s FY2025 earnings at ($1.20) EPS.

A number of other research analysts have also recently commented on VRNA. Truist Financial increased their price target on shares of Verona Pharma from $32.00 to $38.00 and gave the company a buy rating in a research report on Friday, June 28th. Canaccord Genuity Group increased their price target on shares of Verona Pharma from $35.00 to $37.00 and gave the company a buy rating in a research report on Monday, July 22nd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of Buy and a consensus price target of $36.00.

Verona Pharma Trading Up 2.0 %

Shares of VRNA opened at $29.99 on Tuesday. The firm’s 50 day simple moving average is $25.46 and its 200 day simple moving average is $18.74. The company has a market capitalization of $2.44 billion, a P/E ratio of -38.95 and a beta of 0.44. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. Verona Pharma has a 1-year low of $11.39 and a 1-year high of $30.73.

Verona Pharma (NASDAQ:VRNA) last announced its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.53). During the same quarter last year, the firm earned ($0.11) EPS. Sell-side analysts forecast that Verona Pharma will post -2.07 earnings per share for the current fiscal year.

Institutional Trading of Verona Pharma

Large investors have recently added to or reduced their stakes in the stock. CWM LLC bought a new stake in Verona Pharma in the second quarter valued at $29,000. EMC Capital Management purchased a new position in shares of Verona Pharma in the 2nd quarter worth about $38,000. Cape Investment Advisory Inc. purchased a new position in shares of Verona Pharma in the 4th quarter worth about $40,000. Legato Capital Management LLC purchased a new position in shares of Verona Pharma in the 2nd quarter worth about $154,000. Finally, Marshall Wace LLP purchased a new position in Verona Pharma in the 2nd quarter worth about $195,000. Institutional investors own 85.88% of the company’s stock.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.